Is international reference pricing coming to the US?

Perhaps this is what President Trump is exploring. Reuters reports: Drugmakers have been warned that the Trump Administration is considering linking U.S. medicine prices to lower amounts paid by other developed countries, according to two company sources who called the option the pharmaceutical industry’s top concern.Both sources, who were not authorized to speak publicly, said…

Read More

California’s Much-Touted IVF Law May Be Delayed Until 2026, Leaving Many in the Lurch

California lawmakers are poised to delay the state’s much-ballyhooed new law mandating in vitro fertilization insurance coverage for millions, set to take effect July 1. Gov. Gavin Newsom has asked lawmakers to push the implementation date to January 2026, leaving patients, insurers, and employers in limbo. The law, SB 729, requires state-regulated health plans offered…

Read More

Formulary restrictions and health outcomes: A case study in multiple sclerosis

How does formulary restrictions impact health outcomes for patients with multiple sclerosis (MS)? To answer this question, Blaylock, Van Nuys and Joyce (2025) use data 100% Medicare claims data from 2018-2022 covering patients with both prescription drug plans (PDPs) and Medicare Advantage Prescription Drug plans (MA-PDs). Individuals were categorized as above vs. below average formulary…

Read More

Novo Nordisk Turns to Self-Replicating RNA Startup to Discover New Metabolic Medicines

Obesity and type 2 diabetes are among the cardiometabolic diseases included in Novo Nordisk’s R&D pact with Replicate Biosciences, a deal that could pay out up to $550 million. Startup Replicate specializes in therapies and vaccines based on self-replicating RNA. The post Novo Nordisk Turns to Self-Replicating RNA Startup to Discover New Metabolic Medicines appeared…

Read More